Search Results



Search: bristol-myers
Found 43 documents, showing 1 - 10.
[1-10]  [11-20]  [21-30]  [31-40]  [41-43]  [Next >>]
Help
  1. Nonclinical evaluation of the combination of mouse IL-21 and anti- mouse CTLA-4 or PD-1 blocking antibodies in mouse tumor models. | 2013 ASCO Annual Meeting Abstracts
    ... , Stacey Dillon; Bristol-Myers Squibb, Princeton, NJ; Bristol-Myers Squibb, Redwood City, CA; ...
    ... , Princeton, NJ; Bristol-Myers Squibb, Redwood City, CA; Bristol-Myers Squibb, Seattle, WA; ...
    ... , Redwood City, CA; Bristol-Myers Squibb, Seattle, WA; Bristol-Myers Squibb, Mt. Vernon, IN ...
    ... , Seattle, WA; Bristol-Myers Squibb, Mt. Vernon, IN Abstract Disclosures Abstract ...

  2. Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab. | 2013 ASCO Annual Meeting Abstracts
    ... , New York, NY; Bristol-Myers Squibb, Princeton, NJ; Memorial-Sloan Kettering Cancer Center, ...
    ... , New York, NY; Bristol-Myers Squibb, Redwood City, CA; Yale University, New Haven, CT ...

  3. Sequential ipilimumab (Ipi) versus best supportive care (BSC) following first-line chemotherapy (Ctx) in patients (pts) with unresectable locally advanced or metastatic gastric or gastro-esophageal junction (GEJ) cancer: A randomized, open-label, two-arm, phase II trial (CA184-162) of immunotherapy as a maintenance concept. | 2013 ASCO Annual Meeting Abstracts
    ... , Singapore; Bristol-Myers Squibb, Braine-l'Alleud, Belgium; Bristol-Myers Squibb, ...
    ... l'Alleud, Belgium; Bristol-Myers Squibb, Singapore, Singapore; Department of Internal Medicine, ...

  4. Long-term survival in patients with metastatic melanoma who received ipilimumab in four phase II trials. | 2013 ASCO Annual Meeting Abstracts
    ... Beverly Hills, CA; Bristol-Myers Squibb, Wallingford, CT; Bristol-Myers Squibb, Lawrenceville, ...
    ... , Wallingford, CT; Bristol-Myers Squibb, Lawrenceville, NJ; Memorial Sloan-Kettering Cancer ...
    ... , CT; Bristol-Myers Squibb, Lawrenceville, NJ; Memorial Sloan-Kettering Cancer Center, New ...

  5. Role of the immunoglobulin constant region in the antitumor activity of antibodies to cytotoxic T-lymphocyte antigen-4 (CTLA-4). | 2013 ASCO Annual Meeting Abstracts
    ... Chen, Mark Selby; Bristol-Myers Squibb, Redwood City, CA; Bristol-Myers Squibb, Princeton, NJ ...
    ... , Redwood City, CA; Bristol-Myers Squibb, Princeton, NJ Abstract Disclosures Abstract: Background ...
    ... , CA; Bristol-Myers Squibb, Princeton, NJ Abstract Disclosures Abstract: Background: Anti-...

  6. Ipilimumab (Ipi) retreatment at 10 mg/kg in patients with metastatic melanoma previously treated in phase II trials. | 2013 ASCO Annual Meeting Abstracts
    ... Beverly Hills, CA; Bristol-Myers Squibb, Wallingford, CT; Bristol-Myers Squibb, Lawrenceville, ...
    ... , Wallingford, CT; Bristol-Myers Squibb, Lawrenceville, NJ; Memorial Sloan-Kettering Cancer ...
    ... , CT; Bristol-Myers Squibb, Lawrenceville, NJ; Memorial Sloan-Kettering Cancer Center, New ...

  7. Changes in the quality of life of advanced melanoma patients after 12 weeks of treatment with ipilimumab compared to gp100 in a phase III clinical trial. | 2013 ASCO Annual Meeting Abstracts
    ... , United Kingdom; Bristol-Myers Squibb, Rueil-Malmaison, France; Bristol-Myers Squibb, ...
    ... Malmaison, France; Bristol-Myers Squibb, Rueil Malmaison, France; Assistance Publique-H˘pitaux ...

  8. CA184-240: A single-arm, open-label phase II study of vemurafenib followed by ipilimumab in patients with BRAF V600-mutated advanced melanoma (AM). | 2013 ASCO Annual Meeting Abstracts
    ... , Albuquerque, NM; Bristol-Myers Squibb, Braine-l'Alleud, Belgium; Bristol-Myers Squibb, ...
    ... l'Alleud, Belgium; Bristol-Myers Squibb, Wallingford, CT; The Beverly Hills Cancer Center, ...

  9. Phase I dose escalation study of recombinant interleukin-21 (rIL-21, BMS-982470) in combination with ipilimumab (Ipi) in patients (pts) with advanced or metastatic melanoma (MM). | 2013 ASCO Annual Meeting Abstracts
    ... , Seattle, WA; Bristol-Myers Squibb, Seattle, WA; Bristol-Myers Squibb, Princeton, NJ; The ...
    ... , Seattle, WA; Bristol-Myers Squibb, Princeton, NJ; The University of Texas MD Anderson ...

  10. A phase III open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator's choice in advanced melanoma patients progressing post anti-CTLA-4 therapy. | 2013 ASCO Annual Meeting Abstracts
    ... , Nashville, TN; Bristol-Myers Squibb, Princeton, NJ; Bristol-Myers Squibb, Braine-...
    ... , Princeton, NJ; Bristol-Myers Squibb, Braine-l'Alleud, Belgium; H. Lee Moffitt Cancer ...
Results Pages:  [1-10]  [11-20]  [21-30]  [31-40]  [41-43]  [Next >>]